Great post Hieupham! This points out a real tragedy which is also occurring in the USA. By pricing the medication so high initially, Gilead caused the insurance companies here to institute very restrictive access guidelines. Only patients at F3+ currently qualify for treatment under most plans. The tragedy is that as prices are being reduced, the insurance companies are not changing their treatment guidelines. So prices will have to fall still further until more patients are treated. It's even possible that even with further reductions, treatment access will be limited.
It's really up to the individual in USA to save themselves and buy generic meds here through FixHepC.